PeptideGlobal

Zeydovio approval in the EU gives short bowel syndrome patients a twice weekly GLP 2 option

The European Commission authorised Zealand Pharma's glepaglutide, sold as Zeydovio, for adults with short bowel syndrome on 12 November. It is injected twice a week, cut intravenous support in a 106 patient trial, and still lacks a commercial partner.

Illustration for the story: Zeydovio approval in the EU gives short bowel syndrome patients a twice weekly GLP 2 option

Illustration by Peptide Global, not a picture of the place in the story.

The short of itThe European Commission authorised Zealand Pharma's glepaglutide, Zeydovio, a twice weekly GLP-2 analogue for adults with short bowel syndrome, on 12 November 2026.

The Zeydovio approval gives adults with short bowel syndrome in Europe a second peptide treatment that acts on the gut hormone receptor GLP-2. The European Commission authorised Zealand Pharma's glepaglutide on 12 November, two months after a positive opinion from the European Medicines Agency's committee. Zealand says the licence covers all EU member states plus Iceland, Liechtenstein and Norway. The Danish company has no sales partner yet, so the date and price of any launch remain open.

What the Commission approved

According to the EMA product page, Zeydovio is authorised for adults with short bowel syndrome whose condition has stabilised after the gut has adapted following surgery. Short bowel syndrome follows the removal or loss of a large part of the intestine, and many patients depend on fluids and nutrients given into a vein, known as parenteral support. Glepaglutide is a long acting analogue of GLP-2, a hormone that helps the gut lining grow, increases its absorbing surface and slows the passage of food, so the remaining bowel can take up more fluid and nutrients. The medicine is injected under the skin twice a week. The EMA lists it as a medicine under additional monitoring.

The agency's scientific committee, the CHMP, adopted its positive opinion on 17 September, and the Commission decision followed on 12 November, the EMA lists show. Zealand Pharma A/S of Denmark holds the marketing authorisation. In a statement reported by Indian Pharma Post, chief executive Adam Steensberg called the decision "an important milestone" for people with the condition in Europe and "the first major advancement in treatment in more than a decade". The only earlier GLP-2 medicine for the condition was authorised in the EU in 2012, which fits that description. Zealand did not disclose expected patient numbers, a price or a launch order for individual countries.

The trial behind the decision

The main study enrolled 106 adults who needed intravenous fluids and nutrients and compared Zeydovio with placebo over 24 weeks, the EMA summary says. Weekly intravenous support fell by an average of 5.1 litres with the medicine, against 2.9 litres with placebo. Among patients given the twice weekly treatment, 14 percent no longer needed intravenous support at all, while every patient on placebo still did. Zealand describes this pivotal trial as EASE-1 and says it showed a statistically significant reduction in parenteral support. Extension studies called EASE-2 and EASE-3 follow patients for up to two years, and the company expects full results at scientific meetings in 2027.

Among patients given the twice weekly treatment, 14 percent no longer needed intravenous support at all, while every patient on placebo still did.

The safety section reflects a drug that makes gut tissue grow. Common side effects, affecting more than one in ten people, include reactions where the injection is given, stoma problems, abdominal pain, nausea, vomiting, fluid retention and bloating. Serious side effects include bowel blockage and problems in other abdominal organs, and gut polyps were also reported. The medicine must not be used in people with active or suspected cancer, or with certain gut, liver, biliary or pancreatic cancers in the previous five years. Polyps must be removed and the bowel checked before treatment, with gut examinations recommended yearly for the first two years and at least every five years after that.

How it compares with the older GLP 2 option

Europe already has one GLP-2 analogue for this condition. Teduglutide, sold as Revestive by Takeda, was first authorised in the EU on 30 August 2012 and is injected once a day, according to its EMA medicine page. The Zeydovio approval adds a longer acting option that patients inject twice a week instead of daily, a practical difference for people who already manage tubes, stomas and frequent clinic visits. No head to head trial against teduglutide was described in the EMA summary, so it is not possible to say from these documents whether one medicine reduces intravenous support more than the other. Doctors will compare them on dosing burden, side effects and price once both are available.

ItemDetail
MedicineZeydovio, glepaglutide, a GLP-2 analogue
HolderZealand Pharma A/S, Denmark
UseAdults with short bowel syndrome, stable after intestinal adaptation
How givenInjection under the skin twice a week
CHMP opinion17 September 2026
Commission authorisation12 November 2026
TerritoryEU member states plus Iceland, Liechtenstein and Norway
Main study106 adults, 24 weeks, versus placebo
Main resultWeekly intravenous support down 5.1 litres versus 2.9 litres
Commercial partnerNot yet named

The EMA also set conditions that shape how the drug will be used. Treatment must be started by a doctor experienced in short bowel syndrome, and its benefit is reassessed after six months, so patients who do not respond can stop. Weight and nutritional status must be monitored. The agency noted that information beyond two years of treatment was limited when the authorisation was granted, which is one reason the extension studies matter. For national health systems, those rules point to use in specialist intestinal failure centres rather than in general practice, and to a defined review point that payers can build into reimbursement decisions. Pricing talks will run country by country.

Partner search and the US route

Zealand says its focus now is finding the right partner to bring Zeydovio to patients across Europe and beyond, and it is in talks about global commercial rights to glepaglutide. Until a deal is signed, there is no announced launch country or date. In the United States, a separate Phase 3 trial called EASE-5 is running to generate the confirmatory evidence needed for a filing, and the company says recruitment is on track. A small mechanistic study, EASE-4, showed improved intestinal absorption with the drug, according to the company. These details come from Zealand's own statement and have not been independently reviewed beyond what the EMA published for Europe.

For readers following European decisions, the Zeydovio approval is a reminder that peptide medicine is wider than obesity. Gut hormone drugs are best known today through semaglutide and other GLP-1 treatments, but GLP-2 medicines serve a small group of patients with rare intestinal failure, where any cut in intravenous support can mean fewer nights tied to a line and fewer hospital visits. Small patient numbers also mean that price and reimbursement will be set for a small, specialist group of patients. This site tracks such decisions on its Europe desk. It also maps them by country in the story atlas. The next dates to watch are a partnership announcement, the first national pricing decisions, and the full EASE-2 and EASE-3 results promised for 2027.

Conclusion

The Zeydovio approval gives Europe a twice weekly GLP-2 treatment for adults with short bowel syndrome, backed by a 106 patient trial in which intravenous support fell further than with placebo. It comes with strict cancer and polyp checks and a six month review. Launch timing and prices depend on Zealand finding a commercial partner, and long term data are due in 2027.

Why it matters in European Union

Patients with short bowel syndrome in Europe have relied on intravenous feeding and one daily GLP-2 injection since 2012. A twice weekly option could reduce the burden, but launch depends on Zealand finding a partner and on country by country pricing.

What to watch

A commercial partner for glepaglutide, the first national pricing and reimbursement decisions, EASE-2 and EASE-3 results in 2027, and EASE-5 progress toward a US filing.

Sources

  1. European Medicines Agency: Zeydovio EPAR
  2. European Medicines Agency: Revestive EPAR
  3. Indian Pharma Post: Zealand Pharma gets European Commission nod for first major SBS treatment advance in decade

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.